Not exactly news....but sometimes it is nice to recognize how far we've come...
Current status of chimeric antigen
receptor engineered T cell-based and immune checkpoint blockade-based
cancer immunotherapies. Hegde, Mukherji. Cancer Immunol
Immunother. 2017 May 11.
Adoptive cell therapies with chimeric
antigen receptor (CAR) engineered T cells (CAR-T) and immune
checkpoint inhibition (ICI)-based cancer immunotherapies have lately
shown remarkable success in certain tumor types. CAR-T cell-based
therapies targeting CD19 can now induce durable remissions as well as
prolong disease-free survival of patients with CD19 positive
treatment refractory B cell malignancies and ICI-based therapies with
humanized monoclonal antibodies against the T cell inhibitory
receptors CTLA-4 and PD-1 as well as against the PD-1 ligand, PD-L1,
can now achieve durable remissions as well as prolongation of life of
a sizeable fraction of patients with melanoma and Hodgkin's lymphoma
and non-small cell cancers. Most importantly, these
immuno-therapeutic treatment modalities have raised the possibility
of achieving long-term "containment" as well as "cures"
for certain types of cancer. While this represents major advances in
cancer immunotherapy, both modalities come with considerable
toxicities, including fatalities. Although more work will be needed
to bring CAR-T cell-based therapies to the bedside for most major
cancers and a good deal more will be needed to make ICI-alone or in
combination with other treatment modalities-work more consistently
and across most major cancers, these two treatment modalities stand
out as superb examples of successful translation of bench research to
the bedside as well as represent real progress in the field of cancer
immunotherapy.We've come a long way, baby! Thanks to the mice....AND the ratties! Take care. - c
No comments:
Post a Comment